Study of Weekly Clofarabine for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2012-08-01
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 8
- Registration Number
- NCT00081887
- Locations
- 🇺🇸
The University of Texas M.D. Anderson Cancer Center, Houston, Texas, United States
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
- First Posted Date
- 2004-04-27
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 29
- Registration Number
- NCT00081874
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-23
- Last Posted Date
- 2018-10-26
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 7
- Registration Number
- NCT00005092
- Locations
- 🇺🇸
University of Illinois at Chicago, Chicago, Illinois, United States
🇺🇸University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
🇺🇸Washington University Barnard Cancer Center, Saint Louis, Missouri, United States
Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors
- First Posted Date
- 2004-04-22
- Last Posted Date
- 2013-02-18
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 4
- Registration Number
- NCT00002463
- Locations
- 🇺🇸
University of Texas - MD Anderson Cancer Center, Houston, Texas, United States
Nerve-Sparing Radical Prostatectomy With or Without Nerve Grafting Followed by Standard Therapy for Erectile Dysfunction in Treating Patients With Localized Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2012-07-30
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 111
- Registration Number
- NCT00080808
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Neoadjuvant Ifosfamide, Doxorubicin, Gemcitabine, and Cisplatin in Treating Patients Who Are Undergoing Radical Cystectomy for Locally Advanced Carcinoma (Cancer) of the Urothelium
- Conditions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2012-10-22
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 65
- Registration Number
- NCT00080795
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Docetaxel With or Without Imatinib Mesylate in Treating Patients With Androgen-Independent Prostate Cancer and Bone Metastases
- Conditions
- Interventions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2012-10-12
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 116
- Registration Number
- NCT00080678
- Locations
- 🇺🇸
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Memorial Sloan-Kettering Cancer Center, New York, New York, United States
🇺🇸M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Hormone Ablation Therapy, Doxorubicin, and Zoledronate With or Without Strontium 89 in Treating Patients With Androgen-Dependent Prostate Cancer and Bone Metastases
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2016-11-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 80
- Registration Number
- NCT00081159
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at Orlando, Orlando, Florida, United States
🇺🇸M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
🇺🇸CCOP - Marshfield Clinic Research Foundation, Marshfield, Wisconsin, United States
Doxorubicin and Strontium-89 With or Without Celecoxib in Treating Patients With Progressive Androgen-Independent Prostate Cancer and Bone Metastases
- Conditions
- Interventions
- First Posted Date
- 2004-04-08
- Last Posted Date
- 2018-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 14
- Registration Number
- NCT00080782
- Locations
- 🇺🇸
M.D. Anderson Cancer Center at University of Texas, Houston, Texas, United States
Arsenic Trioxide in Treating Patients With Refractory or Relapsed Chronic Lymphocytic Leukemia
- Conditions
- First Posted Date
- 2004-03-25
- Last Posted Date
- 2012-10-10
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT00006090